marked.bio

Drugs

Targeted drugs, antibody-drug conjugates and immunotherapies tested in the biomarker-selected trials on marked.bio. Each page shows approvals with pivotal results, the biomarkers a drug is tested in, and its trials.

Targeted drugs

DrugClassBiomarkersActive trials
osimertinib Approved EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, RET fusion or mutation, ALK fusion, PIK3CA activating mutation, BRCA1/2 mutation, KRAS G12C, KRAS G12D, MET exon 14 skipping 123
cetuximab Approved anti-EGFR antibody KRAS G12C, KRAS G12D, BRAF V600E, MSI-H / dMMR, ALK fusion, EGFR exon 19 deletion / L858R, NTRK1/2/3 fusion, PIK3CA activating mutation, RET fusion or mutation, EGFR exon 20 insertion, HER2 (ERBB2) activating mutation, MET exon 14 skipping 83
olaparib Approved PARP inhibitor BRCA1/2 mutation, IDH1/2 mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), HER2 (ERBB2) activating mutation, KRAS G12C, KRAS G12D, PIK3CA activating mutation, BRAF V600E, EGFR exon 19 deletion / L858R 47
venetoclax BCL-2 inhibitor FLT3 mutation (ITD/TKD), NPM1 mutation, IDH1/2 mutation, KRAS G12C, KRAS G12D, ALK fusion 43
trametinib Approved MEK inhibitor BRAF V600E, KRAS G12C, KRAS G12D, NTRK1/2/3 fusion, ALK fusion, EGFR exon 19 deletion / L858R, RET fusion or mutation, ROS1 fusion, EGFR exon 20 insertion, MET exon 14 skipping, MSI-H / dMMR 42
furmonertinib EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, HER2 (ERBB2) activating mutation 36
dabrafenib Approved BRAF inhibitor BRAF V600E, NTRK1/2/3 fusion, ALK fusion, KRAS G12C, RET fusion or mutation, ROS1 fusion, EGFR exon 20 insertion, KRAS G12D, MSI-H / dMMR 33
encorafenib Approved BRAF inhibitor BRAF V600E, MSI-H / dMMR, ALK fusion, KRAS G12C, KRAS G12D 32
ivosidenib Approved IDH1 inhibitor IDH1/2 mutation, FLT3 mutation (ITD/TKD), FGFR2 fusion or rearrangement 27
gilteritinib Approved FLT3 inhibitor FLT3 mutation (ITD/TKD), NPM1 mutation, ALK fusion, IDH1/2 mutation, EGFR exon 19 deletion / L858R 24
amivantamab Approved EGFR-MET bispecific antibody EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, MET exon 14 skipping, ALK fusion, IDH1/2 mutation, KRAS G12C, MSI-H / dMMR, ROS1 fusion 23
trastuzumab anti-HER2 antibody HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR, PIK3CA activating mutation, HER2 (ERBB2) activating mutation, BRCA1/2 mutation, Claudin 18.2 expression, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D, ALK fusion, BRAF V600E, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), MET exon 14 skipping, RET fusion or mutation 23
aumolertinib EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R, ALK fusion, BRAF V600E, BRCA1/2 mutation, EGFR exon 20 insertion, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ROS1 fusion 22
binimetinib Approved MEK inhibitor BRAF V600E, KRAS G12D, MSI-H / dMMR, KRAS G12C, ALK fusion, EGFR exon 19 deletion / L858R, ROS1 fusion 22
lorlatinib Approved ALK TKI (3rd generation) ALK fusion, ROS1 fusion, BRAF V600E, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D 21
sotorasib Approved KRAS G12C inhibitor (OFF state) KRAS G12C, EGFR exon 19 deletion / L858R, KRAS G12D, MSI-H / dMMR, BRAF V600E 21
adagrasib Approved KRAS G12C inhibitor (OFF state) KRAS G12C, BRAF V600E, KRAS G12D, EGFR exon 19 deletion / L858R 17
alectinib Approved ALK TKI (2nd generation) ALK fusion, ROS1 fusion, BRAF V600E, NTRK1/2/3 fusion, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, KRAS G12C, RET fusion or mutation, MSI-H / dMMR, PIK3CA activating mutation 17
crizotinib Approved ALK/ROS1 TKI (1st generation) ALK fusion, ROS1 fusion, BRAF V600E, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, KRAS G12C, MET exon 14 skipping, MSI-H / dMMR, NTRK1/2/3 fusion, RET fusion or mutation, KRAS G12D 17
abemaciclib Approved CDK4/6 inhibitor PIK3CA activating mutation, ESR1 mutation, IDH1/2 mutation, BRCA1/2 mutation, KRAS G12C, BRAF V600E, EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), KRAS G12D, ALK fusion, MSI-H / dMMR 16
lazertinib Approved EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, MET exon 14 skipping 16
inavolisib Approved PI3Kα inhibitor PIK3CA activating mutation, BRCA1/2 mutation, HER2 (ERBB2) activating mutation, KRAS G12C, ALK fusion, BRAF V600E, MSI-H / dMMR, RET fusion or mutation 15
palbociclib Approved CDK4/6 inhibitor PIK3CA activating mutation, BRCA1/2 mutation, ESR1 mutation, ALK fusion, BRAF V600E, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D, ROS1 fusion, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 15
sunvozertinib Approved EGFR exon 20 insertion TKI EGFR exon 20 insertion, EGFR exon 19 deletion / L858R, ALK fusion, BRAF V600E, HER2 (ERBB2) activating mutation, KRAS G12C, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion 15
ensartinib Approved ALK TKI (2nd generation) ALK fusion, ROS1 fusion, BRAF V600E, EGFR exon 20 insertion, KRAS G12C, MET exon 14 skipping, NTRK1/2/3 fusion, RET fusion or mutation 14
panitumumab Approved anti-EGFR antibody KRAS G12C, KRAS G12D, BRAF V600E, BRCA1/2 mutation, MSI-H / dMMR 14
ribociclib CDK4/6 inhibitor PIK3CA activating mutation, BRAF V600E, ESR1 mutation, ALK fusion, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), KRAS G12C, KRAS G12D, NTRK1/2/3 fusion, ROS1 fusion, IDH1/2 mutation 14
vemurafenib Approved BRAF inhibitor BRAF V600E, ALK fusion, ROS1 fusion, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, KRAS G12C, NTRK1/2/3 fusion, RET fusion or mutation, KRAS G12D, MSI-H / dMMR, PIK3CA activating mutation 14
zolbetuximab Approved anti-CLDN18.2 antibody Claudin 18.2 expression, MSI-H / dMMR 14
alpelisib Approved PI3Kα inhibitor PIK3CA activating mutation, ALK fusion, BRAF V600E, BRCA1/2 mutation, HER2 (ERBB2) activating mutation 13
daraxonrasib RAS(ON) multi-selective inhibitor KRAS G12D, KRAS G12C 13
enasidenib Approved IDH2 inhibitor IDH1/2 mutation, FLT3 mutation (ITD/TKD) 13
niraparib Approved PARP inhibitor BRCA1/2 mutation, IDH1/2 mutation, ALK fusion, BRAF V600E, EGFR exon 19 deletion / L858R, ROS1 fusion, MSI-H / dMMR 13
selpercatinib Approved RET inhibitor RET fusion or mutation, BRAF V600E, ALK fusion, EGFR exon 19 deletion / L858R, MET exon 14 skipping, NTRK1/2/3 fusion, ROS1 fusion 13
vebreltinib MET TKI EGFR exon 19 deletion / L858R, MET exon 14 skipping, IDH1/2 mutation 13
afatinib Approved EGFR TKI (2nd generation) EGFR exon 19 deletion / L858R, KRAS G12C, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), HER2 (ERBB2) activating mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR, EGFR exon 20 insertion, KRAS G12D, NRG1 fusion 12
erdafitinib Approved FGFR inhibitor FGFR3 alteration (mutation or fusion), FGFR2 fusion or rearrangement, MSI-H / dMMR 12
glecirasib KRAS G12C inhibitor (OFF state) KRAS G12C, ALK fusion, BRAF V600E, EGFR exon 20 insertion, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion 12
revumenib Approved menin inhibitor NPM1 mutation, FLT3 mutation (ITD/TKD) 12
vorasidenib Approved brain-penetrant IDH1/2 inhibitor IDH1/2 mutation 11
calderasib KRAS G12C inhibitor (OFF state) KRAS G12C, KRAS G12D, MSI-H / dMMR 10
capivasertib Approved AKT inhibitor PIK3CA activating mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), EGFR exon 19 deletion / L858R, MSI-H / dMMR, BRCA1/2 mutation 10
cobimetinib Approved MEK inhibitor BRAF V600E, ALK fusion, KRAS G12C, KRAS G12D, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, MSI-H / dMMR, PIK3CA activating mutation 10
defactinib Approved FAK inhibitor KRAS G12C, KRAS G12D, ALK fusion, BRAF V600E, IDH1/2 mutation, MSI-H / dMMR, NTRK1/2/3 fusion, RET fusion or mutation 10
erlotinib Approved EGFR TKI (1st generation) EGFR exon 19 deletion / L858R, KRAS G12C, ALK fusion, KRAS G12D, BRAF V600E, HER2 (ERBB2) activating mutation, RET fusion or mutation, EGFR exon 20 insertion, PIK3CA activating mutation, ROS1 fusion 10
garsorasib KRAS G12C inhibitor (OFF state) KRAS G12C 10
olutasidenib Approved IDH1 inhibitor IDH1/2 mutation, FLT3 mutation (ITD/TKD) 10
avutometinib Approved RAF/MEK clamp KRAS G12C, KRAS G12D, ALK fusion, BRAF V600E, IDH1/2 mutation, NTRK1/2/3 fusion, RET fusion or mutation 9
befotertinib EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion 9
limertinib EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R 9
pemigatinib Approved FGFR inhibitor FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), FLT3 mutation (ITD/TKD), IDH1/2 mutation, MSI-H / dMMR 9
PLB1004 EGFR TKI (incl. exon 20 insertions) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, HER2 (ERBB2) activating mutation 9
talazoparib Approved PARP inhibitor BRCA1/2 mutation, KRAS G12C, KRAS G12D, MSI-H / dMMR, IDH1/2 mutation 9
VS-7375 KRAS G12D inhibitor (ON/OFF) KRAS G12D 9
ziftomenib Approved menin inhibitor NPM1 mutation, FLT3 mutation (ITD/TKD) 9
entrectinib Approved TRK/ROS1 TKI ROS1 fusion, ALK fusion, NTRK1/2/3 fusion, BRAF V600E, KRAS G12C, RET fusion or mutation, BRCA1/2 mutation 8
fulzerasib KRAS G12C inhibitor (OFF state) KRAS G12C, KRAS G12D 8
larotrectinib Approved TRK inhibitor NTRK1/2/3 fusion, BRAF V600E, RET fusion or mutation, ALK fusion, EGFR exon 20 insertion, KRAS G12C, ROS1 fusion 8
savolitinib MET TKI EGFR exon 19 deletion / L858R, ALK fusion, BRAF V600E, EGFR exon 20 insertion, KRAS G12C, MET exon 14 skipping, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion, MSI-H / dMMR 8
zoldonrasib KRAS G12D inhibitor (ON state) KRAS G12D, KRAS G12C 8
HRS-4642 KRAS G12D inhibitor KRAS G12D, KRAS G12C 7
ifebemtinib FAK inhibitor KRAS G12C, EGFR exon 19 deletion / L858R, KRAS G12D 7
pertuzumab anti-HER2 antibody PIK3CA activating mutation, MSI-H / dMMR, BRCA1/2 mutation, HER2 (ERBB2) activating mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ALK fusion, BRAF V600E, RET fusion or mutation 7
selumetinib MEK inhibitor KRAS G12C, KRAS G12D, EGFR exon 19 deletion / L858R, BRAF V600E, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 7
tucatinib HER2 TKI HER2-low / ultralow (IHC 1+ or 2+/ISH-), HER2 (ERBB2) activating mutation, EGFR exon 19 deletion / L858R, PIK3CA activating mutation, BRAF V600E 7
brigatinib Approved ALK TKI (2nd generation) ALK fusion, ROS1 fusion 6
divarasib KRAS G12C inhibitor (OFF state) KRAS G12C, ALK fusion, BRAF V600E, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion 6
gefitinib Approved EGFR TKI (1st generation) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion 6
pyrotinib HER2 TKI HER2-low / ultralow (IHC 1+ or 2+/ISH-), ALK fusion, BRAF V600E, ROS1 fusion, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, HER2 (ERBB2) activating mutation, KRAS G12C, NTRK1/2/3 fusion, RET fusion or mutation 6
quizartinib Approved FLT3 inhibitor FLT3 mutation (ITD/TKD), NPM1 mutation 6
rituximab anti-CD20 antibody BRAF V600E, FLT3 mutation (ITD/TKD), ALK fusion, IDH1/2 mutation 6
zongertinib Approved HER2 TKI HER2 (ERBB2) activating mutation 6
adavosertib WEE1 inhibitor BRCA1/2 mutation, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), MSI-H / dMMR, BRAF V600E, FLT3 mutation (ITD/TKD) 5
dacomitinib Approved EGFR TKI (2nd generation) EGFR exon 19 deletion / L858R, ALK fusion, BRAF V600E, BRCA1/2 mutation, ROS1 fusion, KRAS G12C, KRAS G12D 5
everolimus mTOR inhibitor PIK3CA activating mutation, ALK fusion, ESR1 mutation, KRAS G12C, KRAS G12D, BRAF V600E, EGFR exon 19 deletion / L858R, IDH1/2 mutation 5
icotinib EGFR TKI (1st generation) EGFR exon 19 deletion / L858R 5
midostaurin Approved FLT3 inhibitor FLT3 mutation (ITD/TKD), NPM1 mutation 5
pralsetinib Approved RET inhibitor RET fusion or mutation, BRAF V600E, NTRK1/2/3 fusion, ALK fusion, KRAS G12C, ROS1 fusion, EGFR exon 20 insertion 5
repotrectinib Approved ROS1/TRK TKI (next generation) ROS1 fusion, NTRK1/2/3 fusion, ALK fusion, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D 5
safusidenib IDH1 inhibitor IDH1/2 mutation 5
tepotinib Approved MET TKI MET exon 14 skipping, EGFR exon 19 deletion / L858R, ALK fusion 5
tovorafenib Approved pan-RAF inhibitor BRAF V600E, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), KRAS G12C, KRAS G12D 5
zipalertinib EGFR exon 20 insertion TKI EGFR exon 20 insertion, EGFR exon 19 deletion / L858R 5
bleximenib menin inhibitor NPM1 mutation 4
ceralasertib ATR inhibitor BRCA1/2 mutation, IDH1/2 mutation 4
DZD6008 EGFR TKI (brain-penetrant) EGFR exon 19 deletion / L858R 4
elironrasib KRAS G12C inhibitor (ON state) KRAS G12C, KRAS G12D 4
fluzoparib PARP inhibitor BRCA1/2 mutation, BRAF V600E 4
GFH276 RAS inhibitor KRAS G12D, KRAS G12C 4
HSK42360 BRAF inhibitor (paradox breaker, brain-penetrant) BRAF V600E 4
olomorasib KRAS G12C inhibitor (ON/OFF) KRAS G12C 4
saruparib PARP1-selective inhibitor BRCA1/2 mutation 4
setidegrasib KRAS G12D degrader KRAS G12D 4
taletrectinib Approved ROS1 TKI (next generation) ROS1 fusion, NTRK1/2/3 fusion 4
veliparib PARP inhibitor BRCA1/2 mutation, IDH1/2 mutation, EGFR exon 19 deletion / L858R, MSI-H / dMMR 4
WSD0922 EGFR TKI (brain-penetrant) EGFR exon 19 deletion / L858R 4
BBO-10203 RAS:PI3Kα interaction blocker KRAS G12C, KRAS G12D, PIK3CA activating mutation 3
capmatinib Approved MET TKI EGFR exon 19 deletion / L858R, MET exon 14 skipping, ALK fusion, BRAF V600E, ROS1 fusion 3
ceritinib Approved ALK TKI (2nd generation) ALK fusion, ROS1 fusion 3
copanlisib PI3K inhibitor PIK3CA activating mutation, MSI-H / dMMR, BRAF V600E, BRCA1/2 mutation 3
deulorlatinib ALK/ROS1 TKI (3rd generation) ALK fusion, ROS1 fusion 3
glumetinib MET TKI EGFR exon 19 deletion / L858R, MET exon 14 skipping 3
HRS-7058 KRAS G12C inhibitor KRAS G12C 3
ipatasertib AKT inhibitor BRCA1/2 mutation, HER2 (ERBB2) activating mutation, MSI-H / dMMR, PIK3CA activating mutation, ALK fusion, BRAF V600E, RET fusion or mutation 3
iruplinalkib ALK TKI (2nd generation) ALK fusion, ROS1 fusion 3
JYP0322 ROS1 TKI ROS1 fusion 3
MCLA-129 EGFR-MET bispecific antibody EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, MET exon 14 skipping 3
navitoclax BCL-2/BCL-xL inhibitor BRAF V600E, BRCA1/2 mutation, KRAS G12C, KRAS G12D, EGFR exon 19 deletion / L858R 3
NXP900 YES1/SRC inhibitor ALK fusion, EGFR exon 19 deletion / L858R, IDH1/2 mutation 3
opnurasib KRAS G12C inhibitor (OFF state) KRAS G12C 3
paxalisib PI3K/mTOR inhibitor BRAF V600E, KRAS G12C, PIK3CA activating mutation 3
sevabertinib Approved HER2 TKI HER2 (ERBB2) activating mutation 3
silevertinib EGFR TKI (4th generation) EGFR exon 19 deletion / L858R 3
TY-9591 EGFR TKI (deuterated osimertinib) EGFR exon 19 deletion / L858R 3
ZEN-3694 BET bromodomain inhibitor BRAF V600E, KRAS G12C, KRAS G12D, BRCA1/2 mutation 3
APG-2449 FAK/ALK/ROS1 inhibitor ALK fusion, ROS1 fusion 2
BI 1701963 SOS1 inhibitor KRAS G12C, KRAS G12D 2
claturafenib BRAF inhibitor (brain-penetrant) BRAF V600E 2
fexagratinib FGFR inhibitor FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), MSI-H / dMMR 2
futibatinib Approved FGFR inhibitor (irreversible) FGFR2 fusion or rearrangement, KRAS G12C, KRAS G12D, FGFR3 alteration (mutation or fusion) 2
HMBD-001 anti-HER3 antibody NRG1 fusion 2
HMPL-306 IDH1/2 inhibitor IDH1/2 mutation 2
imatinib BCR-ABL/KIT TKI ALK fusion, BRAF V600E, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, KRAS G12D, ROS1 fusion 2
INCB161734 KRAS G12D inhibitor KRAS G12D 2
JMT101 anti-EGFR antibody EGFR exon 19 deletion / L858R, EGFR exon 20 insertion 2
luvometinib MEK inhibitor BRAF V600E, KRAS G12C, KRAS G12D 2
LY3410738 IDH1/2 inhibitor IDH1/2 mutation 2
mirdametinib MEK inhibitor BRAF V600E, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), KRAS G12C, KRAS G12D 2
mobocertinib EGFR exon 20 insertion TKI EGFR exon 20 insertion, EGFR exon 19 deletion / L858R, HER2 (ERBB2) activating mutation 2
naporafenib pan-RAF inhibitor BRAF V600E, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D 2
necitumumab anti-EGFR antibody EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, ALK fusion 2
neladalkib ALK TKI (brain-penetrant, 4th generation) ALK fusion 2
neratinib HER2 TKI HER2 (ERBB2) activating mutation, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D 2
ORIC-114 brain-penetrant EGFR/HER2 inhibitor EGFR exon 20 insertion, EGFR exon 19 deletion / L858R, HER2 (ERBB2) activating mutation 2
plixorafenib BRAF dimer breaker BRAF V600E 2
sitneprotafib SHP2 inhibitor KRAS G12C 2
tinengotinib multi-kinase inhibitor (FGFR) FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 2
TYRA-300 FGFR3-selective inhibitor FGFR3 alteration (mutation or fusion) 2
ulixertinib ERK inhibitor BRAF V600E, KRAS G12C, KRAS G12D, MSI-H / dMMR 2
VVD-133214 WRN helicase inhibitor MSI-H / dMMR 2
ABSK061 FGFR2/3-selective inhibitor FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 1
afuresertib AKT inhibitor PIK3CA activating mutation 1
atebimetinib MEK inhibitor BRAF V600E, KRAS G12C, KRAS G12D 1
AZD9574 PARP1-selective inhibitor (brain-penetrant) BRCA1/2 mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), IDH1/2 mutation 1
batoprotafib SHP2 inhibitor KRAS G12C, ALK fusion, BRAF V600E 1
BBO-8520 KRAS G12C inhibitor (ON/OFF) KRAS G12C 1
belvarafenib pan-RAF inhibitor BRAF V600E, KRAS G12C, KRAS G12D 1
CFT8919 EGFR L858R degrader EGFR exon 19 deletion / L858R 1
derazantinib FGFR inhibitor FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 1
E7386 CBP/β-catenin inhibitor MSI-H / dMMR 1
elzovantinib MET inhibitor MET exon 14 skipping 1
enzomenib menin inhibitor FLT3 mutation (ITD/TKD), NPM1 mutation 1
gedatolisib PI3K/mTOR inhibitor BRCA1/2 mutation, BRAF V600E, KRAS G12C, KRAS G12D, PIK3CA activating mutation 1
gunagratinib FGFR inhibitor FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 1
HMPL-453 FGFR inhibitor FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 1
HRO761 WRN helicase inhibitor MSI-H / dMMR 1
IDH305 IDH1 inhibitor IDH1/2 mutation 1
lapatinib HER2 TKI BRAF V600E, ALK fusion, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D 1
lirafugratinib Approved FGFR2-selective inhibitor FGFR2 fusion or rearrangement 1
lunbotinib RET inhibitor (next generation) RET fusion or mutation 1
nazartinib EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R 1
osemitamab anti-CLDN18.2 antibody Claudin 18.2 expression 1
pamiparib PARP inhibitor IDH1/2 mutation, BRCA1/2 mutation, MSI-H / dMMR 1
RLY-2608 mutant-selective PI3Kα inhibitor PIK3CA activating mutation 1
siremadlin MDM2 inhibitor ALK fusion, BRAF V600E, NTRK1/2/3 fusion, ROS1 fusion, FLT3 mutation (ITD/TKD) 1
ST316 β-catenin antagonist BRCA1/2 mutation 1
STX-478 mutant-selective PI3Kα inhibitor PIK3CA activating mutation 1
SY-5007 RET inhibitor RET fusion or mutation 1
taselisib PI3K inhibitor PIK3CA activating mutation, KRAS G12C, KRAS G12D 1
tasurgratinib FGFR inhibitor FGFR3 alteration (mutation or fusion), FGFR2 fusion or rearrangement 1
TSN1611 KRAS G12D inhibitor KRAS G12D 1
vandetanib multi-kinase inhibitor (RET) RET fusion or mutation 1
vociprotafib SHP2 inhibitor KRAS G12C, EGFR exon 19 deletion / L858R, KRAS G12D 1
zanidatamab HER2 bispecific antibody MSI-H / dMMR, HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1
zenocutuzumab Approved HER2/HER3 bispecific antibody NRG1 fusion, HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1
zidesamtinib Approved ROS1 TKI (brain-penetrant) ROS1 fusion 1
bemarituzumab anti-FGFR2b antibody MSI-H / dMMR 0
berzosertib ATR inhibitor BRCA1/2 mutation 0
BLU-451 EGFR inhibitor EGFR exon 19 deletion / L858R, EGFR exon 20 insertion 0
buparlisib pan-PI3K inhibitor BRAF V600E, EGFR exon 19 deletion / L858R, PIK3CA activating mutation 0
camonsertib ATR inhibitor KRAS G12C, KRAS G12D 0
crenolanib FLT3 inhibitor FLT3 mutation (ITD/TKD) 0
dactolisib PI3K/mTOR inhibitor PIK3CA activating mutation 0
enbezotinib RET inhibitor RET fusion or mutation 0
infigratinib FGFR inhibitor BRAF V600E, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), PIK3CA activating mutation 0
MK-2206 AKT inhibitor BRAF V600E, EGFR exon 19 deletion / L858R, PIK3CA activating mutation 0
MRTX1133 KRAS G12D inhibitor KRAS G12D 0
ponatinib BCR-ABL1 inhibitor ALK fusion, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), FLT3 mutation (ITD/TKD), KRAS G12C, KRAS G12D, RET fusion or mutation 0
poziotinib EGFR/HER2 inhibitor EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, HER2 (ERBB2) activating mutation 0
rezivertinib EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion 0
rociletinib EGFR TKI (3rd generation) EGFR exon 19 deletion / L858R, EGFR exon 20 insertion 0
rogaratinib FGFR inhibitor FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 0
rucaparib Approved PARP inhibitor BRCA1/2 mutation 0
selitrectinib TRK inhibitor (next generation) NTRK1/2/3 fusion 0
senaparib PARP inhibitor BRCA1/2 mutation 0
serabelisib PI3Kα inhibitor KRAS G12C, KRAS G12D, PIK3CA activating mutation 0
seribantumab anti-HER3 antibody NRG1 fusion 0
tarloxotinib pan-HER prodrug EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, HER2 (ERBB2) activating mutation, KRAS G12C, NRG1 fusion 0

Antibody-drug conjugates

DrugClassBiomarkersActive trials
trastuzumab deruxtecan Approved HER2 ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-), HER2 (ERBB2) activating mutation, KRAS G12C, Claudin 18.2 expression, EGFR exon 19 deletion / L858R, BRCA1/2 mutation, EGFR exon 20 insertion, FGFR3 alteration (mutation or fusion), IDH1/2 mutation, KRAS G12D, MSI-H / dMMR 53
trastuzumab rezetecan HER2 ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-), HER2 (ERBB2) activating mutation, Claudin 18.2 expression, EGFR exon 19 deletion / L858R, MSI-H / dMMR 23
sacituzumab tirumotecan TROP2 ADC EGFR exon 19 deletion / L858R, KRAS G12C, ALK fusion, KRAS G12D, MSI-H / dMMR 22
datopotamab deruxtecan Approved TROP2 ADC EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), MET exon 14 skipping, BRCA1/2 mutation, IDH1/2 mutation, BRAF V600E 13
disitamab vedotin HER2 ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-), HER2 (ERBB2) activating mutation, BRCA1/2 mutation, EGFR exon 19 deletion / L858R 12
izalontamab brengitecan EGFR-HER3 bispecific ADC EGFR exon 19 deletion / L858R, KRAS G12C, HER2-low / ultralow (IHC 1+ or 2+/ISH-) 10
IBI343 CLDN18.2 ADC Claudin 18.2 expression 9
LM-302 CLDN18.2 ADC Claudin 18.2 expression, MSI-H / dMMR 9
patritumab deruxtecan HER3 ADC EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), KRAS G12C, KRAS G12D, NRG1 fusion 9
sacituzumab govitecan TROP2 ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-), BRCA1/2 mutation, HER2 (ERBB2) activating mutation, MSI-H / dMMR 8
AZD0901 CLDN18.2 ADC Claudin 18.2 expression 5
BL-M07D1 HER2 ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-), HER2 (ERBB2) activating mutation 5
enfortumab vedotin Nectin-4 ADC BRAF V600E, FGFR3 alteration (mutation or fusion), EGFR exon 19 deletion / L858R, FGFR2 fusion or rearrangement 5
SHR-A1904 CLDN18.2 ADC Claudin 18.2 expression 5
SYS6010 EGFR ADC EGFR exon 19 deletion / L858R 5
YL202 HER3 ADC EGFR exon 19 deletion / L858R, ALK fusion, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ROS1 fusion 5
gemtuzumab ozogamicin CD33 ADC FLT3 mutation (ITD/TKD), NPM1 mutation 4
JS212 EGFR-HER3 bispecific ADC EGFR exon 19 deletion / L858R, ALK fusion, BRAF V600E, HER2 (ERBB2) activating mutation, KRAS G12C, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion 3
rinatabart sesutecan folate receptor alpha ADC BRCA1/2 mutation, EGFR exon 19 deletion / L858R 3
SHR-A2009 HER3 ADC EGFR exon 19 deletion / L858R 3
telisotuzumab adizutecan c-MET ADC EGFR exon 19 deletion / L858R, BRAF V600E 3
trastuzumab emtansine HER2 ADC HER2 (ERBB2) activating mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ALK fusion, BRAF V600E, EGFR exon 19 deletion / L858R, RET fusion or mutation 3
DB-1303 HER2 ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-) 2
HLX43 PD-L1 ADC EGFR exon 19 deletion / L858R 2
HS-20093 B7-H3 ADC KRAS G12C, KRAS G12D 2
JSKN003 HER2 biparatopic ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR 2
telisotuzumab vedotin c-MET ADC EGFR exon 19 deletion / L858R 2
ARX788 HER2 ADC HER2-low / ultralow (IHC 1+ or 2+/ISH-), HER2 (ERBB2) activating mutation 1
brentuximab vedotin CD30 ADC ALK fusion 1
DB-1305 TROP2 ADC ALK fusion, HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1
DB-1311 B7-H3 ADC ALK fusion, HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1

Immunotherapy

DrugClassBiomarkersActive trials
pembrolizumab Approved anti-PD-1 antibody MSI-H / dMMR, KRAS G12C, KRAS G12D, BRAF V600E, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, HER2 (ERBB2) activating mutation, ALK fusion, Claudin 18.2 expression, IDH1/2 mutation, RET fusion or mutation, FGFR3 alteration (mutation or fusion), HER2-low / ultralow (IHC 1+ or 2+/ISH-), NTRK1/2/3 fusion, FGFR2 fusion or rearrangement, PIK3CA activating mutation, ROS1 fusion, MET exon 14 skipping, NPM1 mutation 126
nivolumab Approved anti-PD-1 antibody MSI-H / dMMR, BRAF V600E, KRAS G12C, Claudin 18.2 expression, ALK fusion, EGFR exon 19 deletion / L858R, IDH1/2 mutation, KRAS G12D, BRCA1/2 mutation, ROS1 fusion, HER2 (ERBB2) activating mutation, RET fusion or mutation, FGFR2 fusion or rearrangement, FLT3 mutation (ITD/TKD), HER2-low / ultralow (IHC 1+ or 2+/ISH-), MET exon 14 skipping 73
durvalumab Approved anti-PD-L1 antibody BRCA1/2 mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR, KRAS G12C, Claudin 18.2 expression, FGFR2 fusion or rearrangement, EGFR exon 19 deletion / L858R, IDH1/2 mutation, MET exon 14 skipping, ALK fusion, FGFR3 alteration (mutation or fusion), HER2 (ERBB2) activating mutation, KRAS G12D, PIK3CA activating mutation, ROS1 fusion, BRAF V600E, NTRK1/2/3 fusion 34
ipilimumab Approved anti-CTLA-4 antibody MSI-H / dMMR, BRAF V600E, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D, BRCA1/2 mutation, ROS1 fusion, IDH1/2 mutation, RET fusion or mutation, ALK fusion, FLT3 mutation (ITD/TKD), MET exon 14 skipping 34
tislelizumab anti-PD-1 antibody KRAS G12C, MSI-H / dMMR, Claudin 18.2 expression, KRAS G12D, BRAF V600E, EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ALK fusion, MET exon 14 skipping, BRCA1/2 mutation, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), HER2 (ERBB2) activating mutation 30
atezolizumab Approved anti-PD-L1 antibody MSI-H / dMMR, BRAF V600E, BRCA1/2 mutation, KRAS G12C, EGFR exon 19 deletion / L858R, HER2 (ERBB2) activating mutation, PIK3CA activating mutation, ALK fusion, ROS1 fusion, FGFR2 fusion or rearrangement, KRAS G12D, NTRK1/2/3 fusion, RET fusion or mutation, FGFR3 alteration (mutation or fusion), FLT3 mutation (ITD/TKD), MET exon 14 skipping 27
sintilimab anti-PD-1 antibody MSI-H / dMMR, EGFR exon 19 deletion / L858R, Claudin 18.2 expression, KRAS G12C, BRAF V600E, KRAS G12D, ALK fusion, BRCA1/2 mutation, EGFR exon 20 insertion, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 25
dostarlimab Approved anti-PD-1 antibody MSI-H / dMMR, BRCA1/2 mutation 20
toripalimab anti-PD-1 antibody MSI-H / dMMR, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ALK fusion, BRAF V600E, RET fusion or mutation, Claudin 18.2 expression, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D, MET exon 14 skipping, NTRK1/2/3 fusion, IDH1/2 mutation, ROS1 fusion, BRCA1/2 mutation, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 19
ivonescimab PD-1/VEGF bispecific antibody EGFR exon 19 deletion / L858R, KRAS G12C, ALK fusion, BRAF V600E, Claudin 18.2 expression, HER2-low / ultralow (IHC 1+ or 2+/ISH-), KRAS G12D, MET exon 14 skipping, MSI-H / dMMR, ROS1 fusion 17
adebrelimab anti-PD-L1 antibody KRAS G12C, HER2-low / ultralow (IHC 1+ or 2+/ISH-), KRAS G12D, Claudin 18.2 expression, ALK fusion, MSI-H / dMMR 15
cemiplimab anti-PD-1 antibody BRAF V600E, EGFR exon 19 deletion / L858R, MSI-H / dMMR, ALK fusion, BRCA1/2 mutation, FGFR3 alteration (mutation or fusion), IDH1/2 mutation, KRAS G12C, RET fusion or mutation 11
iparomlimab and tuvonralimab PD-1/CTLA-4 antibody combination MSI-H / dMMR, BRAF V600E, KRAS G12C, KRAS G12D, ALK fusion, Claudin 18.2 expression, EGFR exon 19 deletion / L858R, HER2 (ERBB2) activating mutation, RET fusion or mutation, ROS1 fusion 11
cadonilimab PD-1/CTLA-4 bispecific antibody MSI-H / dMMR, Claudin 18.2 expression, KRAS G12C, KRAS G12D, HER2-low / ultralow (IHC 1+ or 2+/ISH-), HER2 (ERBB2) activating mutation 10
camrelizumab anti-PD-1 antibody BRCA1/2 mutation, MSI-H / dMMR, ALK fusion, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D, BRAF V600E 7
retifanlimab anti-PD-1 antibody IDH1/2 mutation, BRAF V600E, BRCA1/2 mutation, KRAS G12D, MSI-H / dMMR, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 7
serplulimab anti-PD-1 antibody EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D, BRAF V600E, MSI-H / dMMR 7
balstilimab anti-PD-1 antibody KRAS G12C, KRAS G12D, MSI-H / dMMR, BRAF V600E 6
aldesleukin interleukin-2 KRAS G12C, KRAS G12D, ALK fusion, BRAF V600E, FLT3 mutation (ITD/TKD), EGFR exon 19 deletion / L858R, MET exon 14 skipping, RET fusion or mutation 5
pumitamig PD-L1/VEGF bispecific antibody EGFR exon 19 deletion / L858R, ALK fusion, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ROS1 fusion 5
avelumab anti-PD-L1 antibody BRAF V600E, MSI-H / dMMR, ALK fusion, BRCA1/2 mutation, EGFR exon 19 deletion / L858R, IDH1/2 mutation, KRAS G12C, KRAS G12D, MET exon 14 skipping 4
botensilimab anti-CTLA-4 antibody (Fc-enhanced) KRAS G12C, KRAS G12D, MSI-H / dMMR, BRAF V600E 4
satricabtagene autoleucel CLDN18.2 CAR-T Claudin 18.2 expression 4
benmelstobart anti-PD-L1 antibody Claudin 18.2 expression, KRAS G12C, MSI-H / dMMR, ALK fusion, EGFR exon 19 deletion / L858R 3
QLS31905 CLDN18.2 T-cell engager Claudin 18.2 expression 3
relatlimab anti-LAG-3 antibody MSI-H / dMMR, BRAF V600E 3
tremelimumab anti-CTLA-4 antibody BRCA1/2 mutation, KRAS G12C, KRAS G12D, MSI-H / dMMR, EGFR exon 19 deletion / L858R 3
budigalimab anti-PD-1 antibody BRAF V600E, EGFR exon 19 deletion / L858R, IDH1/2 mutation 2
ELI-002 KRAS cancer vaccine KRAS G12C, KRAS G12D 2
IBI363 PD-1/IL-2α-bias fusion protein EGFR exon 19 deletion / L858R, ALK fusion, RET fusion or mutation 2
KL-A167 anti-PD-L1 antibody EGFR exon 19 deletion / L858R, MSI-H / dMMR 2
KN046 PD-L1/CTLA-4 bispecific antibody BRAF V600E, MSI-H / dMMR 2
MVA-209 neoantigen vaccine MSI-H / dMMR 2
oleclumab anti-CD73 antibody EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR 2
spartalizumab anti-PD-1 antibody BRAF V600E, MSI-H / dMMR, ALK fusion, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D 2
TG01 RAS peptide vaccine KRAS G12C, KRAS G12D 2
AGEN2373 CD137 agonist antibody KRAS G12C, KRAS G12D, BRAF V600E 1
AU-007 IL-2-redirecting antibody ALK fusion, BRAF V600E 1
BNT116 mRNA cancer vaccine ALK fusion, EGFR exon 19 deletion / L858R, RET fusion or mutation 1
gotistobart anti-CTLA-4 antibody ALK fusion, EGFR exon 19 deletion / L858R, RET fusion or mutation 1
IMT-009 anti-CD161 antibody BRCA1/2 mutation, MSI-H / dMMR 1
JS207 PD-1/VEGF bispecific antibody ALK fusion, BRAF V600E, EGFR exon 19 deletion / L858R, HER2 (ERBB2) activating mutation, KRAS G12C, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion 1
OSE2101 neoepitope cancer vaccine BRAF V600E, KRAS G12C 1
RAPA-201 rapamycin-resistant T-cell therapy ALK fusion 1
tiragolumab anti-TIGIT antibody EGFR exon 19 deletion / L858R, MSI-H / dMMR 1
zimberelimab anti-PD-1 antibody KRAS G12C, KRAS G12D, EGFR exon 19 deletion / L858R, MSI-H / dMMR 1
lifileucel TIL therapy BRAF V600E 0
penpulimab anti-PD-1 antibody HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR 0

Anti-angiogenic drugs

DrugClassBiomarkersActive trials
bevacizumab Approved anti-VEGF antibody KRAS G12C, EGFR exon 19 deletion / L858R, KRAS G12D, BRAF V600E, BRCA1/2 mutation, MSI-H / dMMR, ALK fusion, HER2-low / ultralow (IHC 1+ or 2+/ISH-), EGFR exon 20 insertion, HER2 (ERBB2) activating mutation, IDH1/2 mutation, PIK3CA activating mutation, RET fusion or mutation, ROS1 fusion, FGFR2 fusion or rearrangement, MET exon 14 skipping 82
anlotinib multi-kinase inhibitor EGFR exon 19 deletion / L858R, KRAS G12C, HER2-low / ultralow (IHC 1+ or 2+/ISH-), KRAS G12D, BRAF V600E, Claudin 18.2 expression, MSI-H / dMMR, NTRK1/2/3 fusion, RET fusion or mutation, ALK fusion, BRCA1/2 mutation, EGFR exon 20 insertion, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 19
fruquintinib VEGFR TKI MSI-H / dMMR, BRAF V600E, BRCA1/2 mutation, KRAS G12C, KRAS G12D, Claudin 18.2 expression, ALK fusion, EGFR exon 19 deletion / L858R 11
lenvatinib multi-kinase inhibitor MSI-H / dMMR, RET fusion or mutation, EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ALK fusion, BRAF V600E, IDH1/2 mutation, NTRK1/2/3 fusion, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), KRAS G12C, ROS1 fusion 10
regorafenib multi-kinase inhibitor MSI-H / dMMR, BRAF V600E, KRAS G12C, KRAS G12D, ALK fusion, NTRK1/2/3 fusion, ROS1 fusion 10
apatinib VEGFR2 TKI Claudin 18.2 expression, BRCA1/2 mutation, MSI-H / dMMR, ALK fusion, EGFR exon 19 deletion / L858R, KRAS G12C, KRAS G12D, RET fusion or mutation 9
cabozantinib multi-kinase inhibitor RET fusion or mutation, BRAF V600E, NTRK1/2/3 fusion, KRAS G12C, KRAS G12D, ROS1 fusion, ALK fusion, EGFR exon 19 deletion / L858R, HER2 (ERBB2) activating mutation, MSI-H / dMMR, BRCA1/2 mutation, MET exon 14 skipping 9
ramucirumab Approved anti-VEGFR2 antibody EGFR exon 19 deletion / L858R, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ALK fusion, Claudin 18.2 expression, KRAS G12C, KRAS G12D, MET exon 14 skipping, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), MSI-H / dMMR 9
zanzalintinib multi-kinase inhibitor BRAF V600E, MSI-H / dMMR 3
axitinib VEGFR TKI ALK fusion, MSI-H / dMMR, BRAF V600E, BRCA1/2 mutation, MET exon 14 skipping 2
sorafenib multi-kinase inhibitor FLT3 mutation (ITD/TKD), ALK fusion, BRAF V600E, KRAS G12C, KRAS G12D 2
surufatinib multi-kinase inhibitor ALK fusion, BRAF V600E, EGFR exon 19 deletion / L858R, MET exon 14 skipping, NTRK1/2/3 fusion, RET fusion or mutation, ROS1 fusion 1
sunitinib multi-kinase inhibitor (VEGFR) FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion), FLT3 mutation (ITD/TKD), RET fusion or mutation 0

Hormonal therapy

DrugClassBiomarkersActive trials
fulvestrant Approved oestrogen receptor degrader PIK3CA activating mutation, BRCA1/2 mutation, HER2 (ERBB2) activating mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), ESR1 mutation, KRAS G12C, KRAS G12D, ALK fusion, EGFR exon 19 deletion / L858R, FGFR2 fusion or rearrangement, FGFR3 alteration (mutation or fusion) 38
letrozole aromatase inhibitor PIK3CA activating mutation, BRCA1/2 mutation, ESR1 mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), MSI-H / dMMR, ALK fusion, EGFR exon 19 deletion / L858R 10
elacestrant Approved oral SERD ESR1 mutation, PIK3CA activating mutation, BRCA1/2 mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-) 9
anastrozole aromatase inhibitor PIK3CA activating mutation, HER2-low / ultralow (IHC 1+ or 2+/ISH-), BRCA1/2 mutation, ESR1 mutation, ALK fusion, EGFR exon 19 deletion / L858R 7
abiraterone Approved androgen synthesis inhibitor BRCA1/2 mutation, MSI-H / dMMR, NRG1 fusion 3
enzalutamide Approved androgen receptor inhibitor BRCA1/2 mutation, NRG1 fusion, MSI-H / dMMR 3
camizestrant Approved oral SERD BRCA1/2 mutation, ESR1 mutation 2
giredestrant oral SERD PIK3CA activating mutation 1
imlunestrant Approved oral SERD PIK3CA activating mutation 1
lasofoxifene SERM ESR1 mutation 1
vepdegestrant Approved ER PROTAC degrader 0